CAR T-cell therapy for solid tumors that test positive for GPC3
Part of Cancer, Digestive system clinical trials.
This study tests a new kind of immune therapy called CAR T-cells that are specially designed to find and attack cancer cells that carry a protein called GPC3. Researchers want to see if this treatment is safe and helpful for people with solid tumors that have not responded to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that tests positive for a protein called GPC3.
- You should be well enough to care for yourself (Karnofsky score at least 60%).
- Your doctor expects you to live at least 16 weeks.
- Your cancer must have returned or not responded after at least one or two rounds of standard treatment.
- You cannot have had an organ transplant or be HIV positive.
- You cannot be pregnant or breastfeeding, and if sexually active, you must use birth control for 3 months after the infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
Hear when a new Solid Tumor (Excluding CNS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.